ZEB1 plays a fundamental role in tumour progression and confers a poorer clinical outcome in cancer; nevertheless, PI3K-targeted therapy can suppress the metastatic drive by ZEB1, representing a novel treatment target in nodBCC [38]. Here, ZEB1 is linked to neoplasm.